Rivaroxaban Does Not Reduce VTE Incidence in High-Risk Cancer Patients

THURSDAY, Feb. 21, 2019 -- In high-risk ambulatory patients with cancer, the incidence of venous thromboembolism or death due to venous thromboembolism during 180 days is not significantly reduced for rivaroxaban compared with placebo, according to...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news